Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, Poland.
Front Immunol. 2023 Jun 2;14:1207641. doi: 10.3389/fimmu.2023.1207641. eCollection 2023.
Chronic inflammatory diseases of the lung are some of the leading causes of mortality and significant morbidity worldwide. Despite the tremendous burden these conditions put on global healthcare, treatment options for most of these diseases remain scarce. Inhaled corticosteroids and beta-adrenergic agonists, while effective for symptom control and widely available, are linked to severe and progressive side effects, affecting long-term patient compliance. Biologic drugs, in particular peptide inhibitors and monoclonal antibodies show promise as therapeutics for chronic pulmonary diseases. Peptide inhibitor-based treatments have already been proposed for a range of diseases, including infectious disease, cancers and even Alzheimer disease, while monoclonal antibodies have already been implemented as therapeutics for a range of conditions. Several biologic agents are currently being developed for the treatment of asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and pulmonary sarcoidosis. This article is a review of the biologics already employed in the treatment of chronic inflammatory pulmonary diseases and recent progress in the development of the most promising of those treatments, with particular focus on randomised clinical trial outcomes.
慢性肺部炎症性疾病是全球范围内导致死亡和重大发病的主要原因之一。尽管这些疾病给全球医疗保健带来了巨大负担，但大多数疾病的治疗选择仍然有限。吸入皮质类固醇和β-肾上腺素能激动剂虽然对症状控制有效且广泛可用，但与严重且进行性的副作用相关，影响长期患者依从性。生物药物，特别是肽抑制剂和单克隆抗体，作为慢性肺部疾病的治疗方法显示出希望。肽抑制剂为一系列疾病（包括传染病、癌症甚至阿尔茨海默病）提供了治疗方案，而单克隆抗体已被用于一系列疾病的治疗。目前有几种生物制剂正在开发用于治疗哮喘、慢性阻塞性肺疾病、特发性肺纤维化和肺结节病。本文综述了已用于治疗慢性炎症性肺部疾病的生物制剂，以及这些治疗方法中最有前途的方法的最新进展，特别关注随机临床试验结果。
